Výsledky vyhledávání

Akademický článek

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.

Autor: Ferrante M; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium. Electronic address: marc.ferrante@uzleuven.be., D'Haens G; Inflammatory Bowel Disease Centre, Amsterdam University Medical Center, Amsterdam, Netherlands., Jairath V; Department of Medicine, Division of Gastroenterology, Western University, London, ON, Canada., Danese S; Gastroenterology and Gastrointestinal Endoscopy Unit, Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy., Chen M; Division of Gastroenterology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Ghosh S; APC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland., Hisamatsu T; Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan., Kierkus J; Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The Children's Memorial Health Institute, Warsaw, Poland., Siegmund B; Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité - Universitätsmedizin Berlin, Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Germany., Bragg SM; Eli Lilly and Company, Indianapolis, IN, USA., Crandall W; Eli Lilly and Company, Indianapolis, IN, USA., Durand F; Eli Lilly and Company, Indianapolis, IN, USA., Hon E; Eli Lilly and Company, Indianapolis, IN, USA., Lin Z; Eli Lilly and Company, Indianapolis, IN, USA., Lopes MU; Eli Lilly and Company, Indianapolis, IN, USA., Morris N; Eli Lilly and Company, Indianapolis, IN, USA., Protic M; Eli Lilly and Company, Indianapolis, IN, USA., Carlier H; Eli Lilly and Company, Indianapolis, IN, USA., Sands BE; Dr Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Publikováno v: Lancet (London, England) [Lancet] 2024 Dec 14; Vol. 404 (10470), pp. 2423-2436. Date of Electronic Publication: 2024 Nov 21.

Zobrazit plný text záznamu

Akademický článek

Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial.

Autor: Magro F; Department of Biomedicine, Faculty of Medicine of the University of Porto, Porto, Portugal., Protic M; Medical Gastroenterology, Eli Lilly and Company, Indianapolis, Indiana. Electronic address: nedeljkovic_protic_marijana@lilly.com., De Hertogh G; Department of Pathology, University Hospitals Leuven, Leuven, Belgium., Chan LS; Medical Gastroenterology, Eli Lilly and Company, Indianapolis, Indiana., Pollack P; Medical Gastroenterology, Eli Lilly and Company, Indianapolis, Indiana., Jairath V; Division of Gastroenterology, Western University, London, Ontario, Canada., Carlier H; Medical Gastroenterology, Eli Lilly and Company, Indianapolis, Indiana., Hon E; Medical Gastroenterology, Eli Lilly and Company, Indianapolis, Indiana., Feagan BG; Alimentiv, Inc, London, Canada., Harpaz N; Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York., Pai R; Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale, Arizona., Reinisch W; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.

Publikováno v: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2024 Sep; Vol. 22 (9), pp. 1878-1888.e10. Date of Electronic Publication: 2023 Nov 20.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání